Inovio announces positive interim phase 1 data for ino-4800 vaccine for covid-19

Inovio announces positive interim phase 1 data for ino-4800 vaccine for covid-19.inovio pharma - 94% of phase 1 trial participants demonstrated overall immune responses at week 6 after 2 doses of ino-4800 in trial with 40 healthy volunteers.inovio pharmaceuticals - inovio to begin u.s. phase 2/3 efficacy study this summer upon regulatory concurrence.inovio pharmaceuticals inc - through week 8 ino-4800 regimen was deemed safe and well-tolerated with no serious adverse events.inovio pharma - in preclinical animal challenge study, ino-4800 provided full protection against sars-cov-2 replication in lungs in mice challenged with virus.
INO Ratings Summary
INO Quant Ranking